Denne siden ble automatisk oversatt og nøyaktigheten av oversettelsen er ikke garantert. Vennligst referer til engelsk versjon for en kildetekst.

A Superiority Study of Model-Guided Optimized Dosing Versus Empirical Dosing of Piperacillin/Tazobactam in the Treatment of Community-Acquired Pneumonia in Elderly Patients

15. november 2026 oppdatert av: Wei Zhao, Shandong University

A Randomized Superiority Study Comparing Model-Guided Optimized Dosing With Empirical Dosing of Piperacillin/Tazobactam in Elderly Patients With Community-Acquired Pneumonia

This study tests a new way to give an antibiotic to older adults with pneumonia. Pneumonia is a lung infection.

Piperacillin-tazobactam is an antibiotic. Doctors often use it to treat pneumonia in older adults. Right now, doctors usually give this drug every 8 hours. They let it drip into the vein over 3 hours.

But early research suggests a different schedule may work better. This study will test giving the drug every 6 hours. The drip will last 4 hours. Researchers think this may help the drug fight germs better.

The study will compare the usual schedule with the new schedule. Participants will join one of two groups. One group will get the usual schedule. The other group will get the new schedule.

Researchers will check how well the drug works. They will also watch for side effects. They want to find the safest and most helpful way to give this drug.

Adults aged 65 and older with community-acquired pneumonia can join. Community-acquired pneumonia is a lung infection that starts outside of a hospital.

Studieoversikt

Studietype

Intervensjonell

Registrering (Antatt)

118

Fase

  • Fase 2

Kontakter og plasseringer

Denne delen inneholder kontaktinformasjon for de som utfører studien, og informasjon om hvor denne studien blir utført.

Studiekontakt

Studiesteder

    • Shandong
      • Jinan, Shandong, Kina, 250000
        • Rekruttering
        • Shandong Provincial Public Health Clinical Center

Deltakelseskriterier

Forskere ser etter personer som passer til en bestemt beskrivelse, kalt kvalifikasjonskriterier. Noen eksempler på disse kriteriene er en persons generelle helsetilstand eller tidligere behandlinger.

Kvalifikasjonskriterier

Alder som er kvalifisert for studier

65 år til 110 år (Eldre voksen)

Tar imot friske frivillige

Nei

Kjønn som er kvalifisert for studier

Alle

Beskrivelse

Inclusion Criteria:

  • Age ≥ 65 years;
  • Clinically diagnosed or highly suspected community-acquired pneumonia (CAP). CAP clinical diagnostic criteria: All three of the following must be met:

Onset in the community setting;

At least one of the following clinical manifestations:

New-onset cough, sputum production, or worsening of pre-existing respiratory symptoms, with or without purulent sputum, chest pain, dyspnea, or hemoptysis; Fever; Signs of pulmonary consolidation and/or moist rales; Peripheral white blood cell count > 10×10⁹/L or < 4×10⁹/L, with or without left shift; Chest imaging showing new patchy infiltrates, lobar/segmental consolidation, ground-glass opacities, or interstitial changes, with or without pleural effusion.

For patients aged ≥ 65 years with a body temperature < 38°C, the presence of clear clinical signs of pneumonia and abnormal chest X-ray findings will also be considered meeting the inclusion criteria.

  • At least one of the following risk factors for drug-resistant pathogens:

Comorbidities such as chronic cardiopulmonary disease, diabetes mellitus, renal failure, etc.; Use of broad-spectrum antibiotics within the past 3 months; History of repeated hospitalizations or residence in a long-term care facility;

  • Patients are required to initiate intravenous empiric antimicrobial therapy, and piperacillin-tazobactam is considered appropriate empiric treatment.
  • Expected length of hospital stay ≥ 72 hours;
  • Signed informed consent form.

Exclusion Criteria:

  • Highly suspected or confirmed fungal pneumonia or viral pneumonia;
  • Concurrent use of broad-spectrum antibiotics with similar antibacterial spectra, including cefoperazone-sulbactam, imipenem-cilastatin, meropenem, biapenem and others;
  • Patients with severe allergy to β-lactams and history of severe adverse reactions;
  • End-stage diseases with expected survival time shorter than the treatment course, such as advanced malignant tumors and end-stage organ failure;
  • Severe renal insufficiency with creatinine clearance <40 mL/min, or patients receiving continuous renal replacement therapy (CRRT);
  • Any other conditions deemed ineligible for enrollment by investigators.

Post-randomization exclusion criteria:

  • Isolated fungal infection;
  • Isolated viral infection;
  • Patients with confirmed pathogenic bacteria resistant to piperacillin-tazobactam (PIP/TAZO) during the study.

Studieplan

Denne delen gir detaljer om studieplanen, inkludert hvordan studien er utformet og hva studien måler.

Hvordan er studiet utformet?

Designdetaljer

  • Primært formål: Behandling
  • Tildeling: Randomisert
  • Intervensjonsmodell: Parallell tildeling
  • Masking: Ingen (Open Label)

Våpen og intervensjoner

Deltakergruppe / Arm
Intervensjon / Behandling
Aktiv komparator: guideline-based conventional dosing

Control arm (guideline-based conventional dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 3-hour intravenous infusion every 8 hours (q8h), for a total treatment course of 5-14 days.

Eksperimentell: Model-guided optimized dosing

Intervention arm (model-guided optimized dosing): Piperacillin Sodium and Tazobactam Sodium for Injection (Bangda®) 4500 mg administered as a 4-hour intravenous infusion every 6 hours (q6h), for a total treatment course of 5-14 days. This arm adopts increased dosing frequency and prolonged infusion duration compared with the control arm.

Hva måler studien?

Primære resultatmål

Resultatmål
Tidsramme
The proportion of patients achieving the predefined pharmacodynamic (PD) target.
Tidsramme: up to 1 month
up to 1 month

Sekundære resultatmål

Resultatmål
Tidsramme
Clinical improvement rate after 3 days of empiric therapy
Tidsramme: Day 3
Day 3
Length of hospital stay
Tidsramme: through hospital discharge, an average of 2 weeks
through hospital discharge, an average of 2 weeks
Treatment success rate
Tidsramme: through hospital discharge, an average of 4 weeks
through hospital discharge, an average of 4 weeks
Adverse event (AE) incidence rate
Tidsramme: through end of study-drug treatment, an average of 7 days
through end of study-drug treatment, an average of 7 days

Samarbeidspartnere og etterforskere

Det er her du vil finne personer og organisasjoner som er involvert i denne studien.

Publikasjoner og nyttige lenker

Den som er ansvarlig for å legge inn informasjon om studien leverer frivillig disse publikasjonene. Disse kan handle om alt relatert til studiet.

Hjelpsomme linker

Studierekorddatoer

Disse datoene sporer fremdriften for innsending av studieposter og sammendragsresultater til ClinicalTrials.gov. Studieposter og rapporterte resultater gjennomgås av National Library of Medicine (NLM) for å sikre at de oppfyller spesifikke kvalitetskontrollstandarder før de legges ut på det offentlige nettstedet.

Studer hoveddatoer

Studiestart (Faktiske)

17. juli 2026

Primær fullføring (Antatt)

31. mai 2027

Studiet fullført (Antatt)

31. mai 2027

Datoer for studieregistrering

Først innsendt

20. mai 2026

Først innsendt som oppfylte QC-kriteriene

15. november 2026

Først lagt ut (Faktiske)

18. november 2026

Oppdateringer av studieposter

Sist oppdatering lagt ut (Faktiske)

18. november 2026

Siste oppdatering sendt inn som oppfylte QC-kriteriene

15. november 2026

Sist bekreftet

1. juli 2026

Mer informasjon

Begreper knyttet til denne studien

Plan for individuelle deltakerdata (IPD)

Planlegger du å dele individuelle deltakerdata (IPD)?

NEI

IPD-planbeskrivelse

Individual participant data (IPD) will not be shared due to patient privacy and confidentiality regulations, and the lack of specific informed consent for public data sharing.

Legemiddel- og utstyrsinformasjon, studiedokumenter

Studerer et amerikansk FDA-regulert medikamentprodukt

Nei

Studerer et amerikansk FDA-regulert enhetsprodukt

Nei

Denne informasjonen ble hentet direkte fra nettstedet clinicaltrials.gov uten noen endringer. Hvis du har noen forespørsler om å endre, fjerne eller oppdatere studiedetaljene dine, vennligst kontakt register@clinicaltrials.gov. Så snart en endring er implementert på clinicaltrials.gov, vil denne også bli oppdatert automatisk på nettstedet vårt. .

Abonnere